1	Gen-Probe	NNP	2	nn
2	Inc.	NNP	8	nsubj
3	,	,	2	punct
4	a	DT	6	det
5	biotechnology	NN	6	nn
6	concern	NN	2	appos
7	,	,	2	punct
8	said	VBD	0	root
9	it	PRP	10	nsubj
10	signed	VBD	8	ccomp
11	a	DT	13	det
12	definitive	JJ	13	amod
13	agreement	NN	10	dobj
14	to	TO	16	aux
15	be	VB	16	auxpass
16	acquired	VBN	13	infmod
17	by	IN	16	prep
18	Chugai	NNP	19	nn
19	Pharmaceutical	NNP	20	nn
20	Co.	NNP	17	pobj
21	of	IN	20	prep
22	Tokyo	NNP	21	pobj
23	for	IN	16	prep
24	about	RB	25	quantmod
25	$	$	23	pobj
26	110	CD	25	number
27	million	CD	25	number
28	,	,	25	punct
29	or	CC	25	cc
30	almost	RB	31	quantmod
31	double	RB	34	num
32	the	DT	34	det
33	market	NN	34	nn
34	price	NN	25	conj
35	of	IN	34	prep
36	Gen-Probe	NNP	38	poss
37	's	POS	36	possessive
38	stock	NN	35	pobj
39	.	.	8	punct

1	The	DT	2	det
2	move	NN	4	nsubj
3	is	VBZ	4	cop
4	sure	JJ	0	root
5	to	TO	6	aux
6	heighten	VB	4	xcomp
7	concerns	NNS	6	dobj
8	about	IN	7	prep
9	increased	VBN	11	amod
10	Japanese	JJ	11	amod
11	investment	NN	8	pobj
12	in	IN	11	prep
13	U.S.	NNP	15	nn
14	biotechnology	NN	15	nn
15	firms	NNS	12	pobj
16	.	.	4	punct

1	It	PRP	4	nsubj
2	is	VBZ	4	cop
3	also	RB	4	advmod
4	likely	JJ	0	root
5	to	TO	6	aux
6	bolster	VB	4	xcomp
7	fears	NNS	6	dobj
8	that	IN	12	complm
9	the	DT	10	det
10	Japanese	NNP	12	nsubj
11	will	MD	12	aux
12	use	VB	7	ccomp
13	their	PRP$	14	poss
14	foothold	NN	12	dobj
15	in	IN	14	prep
16	U.S.	NNP	18	nn
17	biotechnology	NN	18	nn
18	concerns	NNS	15	pobj
19	to	TO	20	aux
20	gain	VB	12	xcomp
21	certain	JJ	25	amod
22	trade	NN	25	nn
23	and	CC	22	cc
24	competitive	JJ	22	conj
25	advantages	NNS	20	dobj
26	.	.	4	punct

1	Gen-Probe	NNP	25	nsubj
2	,	,	1	punct
3	an	DT	5	det
4	industry	NN	5	nn
5	leader	NN	1	appos
6	in	IN	5	prep
7	the	DT	8	det
8	field	NN	6	pobj
9	of	IN	8	prep
10	genetic	JJ	11	amod
11	probes	NNS	9	pobj
12	,	,	11	punct
13	which	WDT	17	nsubj
14	is	VBZ	17	cop
15	a	DT	17	det
16	new	JJ	17	amod
17	technology	NN	11	rcmod
18	used	VBN	17	partmod
19	in	IN	18	prep
20	diagnostic	JJ	21	amod
21	tests	NNS	19	pobj
22	,	,	1	punct
23	last	JJ	24	amod
24	year	NN	25	tmod
25	signed	VBD	0	root
26	an	DT	27	det
27	agreement	NN	25	dobj
28	for	IN	32	mark
29	Chugai	NNP	32	nsubj
30	to	TO	32	aux
31	exclusively	RB	32	advmod
32	market	VB	27	ccomp
33	its	PRP$	35	poss
34	diagnostic	JJ	35	amod
35	products	NNS	32	dobj
36	in	IN	32	prep
37	Japan	NNP	36	pobj
38	for	IN	32	prep
39	infectious	JJ	40	amod
40	diseases	NNS	38	pobj
41	and	CC	40	cc
42	cancer	NN	40	conj
43	.	.	25	punct

1	Chugai	NNP	2	nsubj
2	agreed	VBD	0	root
3	then	RB	2	advmod
4	to	TO	5	aux
5	fund	VB	2	xcomp
6	certain	JJ	11	amod
7	associated	VBN	11	amod
8	research	NN	11	nn
9	and	CC	8	cc
10	development	NN	8	conj
11	costs	NNS	5	dobj
12	.	.	2	punct

1	That	DT	2	det
2	arrangement	NN	5	nsubj
3	apparently	RB	5	advmod
4	has	VBZ	5	aux
5	worked	VBN	0	root
6	well	RB	5	advmod
7	,	,	5	punct
8	and	CC	5	cc
9	Thomas	NNP	11	nn
10	A.	NNP	11	nn
11	Bologna	NNP	25	nsubj
12	,	,	11	punct
13	president	NN	11	appos
14	and	CC	13	cc
15	chief	JJ	17	amod
16	executive	JJ	17	amod
17	officer	NN	13	conj
18	of	IN	13	prep
19	Gen-Probe	NNP	18	pobj
20	,	,	19	punct
21	founded	VBN	19	partmod
22	in	IN	21	prep
23	1983	CD	22	pobj
24	,	,	11	punct
25	said	VBD	5	conj
26	the	DT	27	det
27	sale	NN	31	nsubj
28	of	IN	27	prep
29	the	DT	30	det
30	company	NN	28	pobj
31	means	VBZ	25	ccomp
32	``	``	36	punct
33	we	PRP	36	nsubj
34	will	MD	36	aux
35	be	VB	36	cop
36	able	JJ	31	ccomp
37	to	TO	38	aux
38	concentrate	VB	36	xcomp
39	on	IN	38	prep
40	running	VBG	39	pcomp
41	the	DT	42	det
42	business	NN	40	dobj
43	rather	RB	40	cc
44	than	IN	43	mwe
45	always	RB	46	advmod
46	looking	VBG	40	conj
47	for	IN	46	prep
48	sources	NNS	47	pobj
49	of	IN	48	prep
50	financing	NN	49	pobj
51	.	.	5	punct
52	''	''	5	punct

1	Chugai	NNP	2	nsubj
2	agreed	VBD	0	root
3	to	TO	4	aux
4	pay	VB	2	xcomp
5	$	$	4	dobj
6	6.25	CD	5	num
7	a	DT	8	det
8	share	NN	5	npadvmod
9	for	IN	4	prep
10	Gen-Probe	NNP	15	poss
11	's	POS	10	possessive
12	17.6	CD	13	number
13	million	CD	15	num
14	common	JJ	15	amod
15	shares	NNS	9	pobj
16	outstanding	JJ	15	amod
17	on	IN	4	prep
18	a	DT	21	det
19	fully	RB	20	advmod
20	diluted	VBN	21	amod
21	basis	NN	17	pobj
22	.	.	2	punct

1	Yesterday	NN	13	tmod
2	,	,	13	punct
3	in	IN	13	prep
4	national	JJ	5	amod
5	trading	NN	3	pobj
6	in	IN	5	prep
7	the	DT	9	det
8	over-the-counter	JJ	9	amod
9	market	NN	6	pobj
10	,	,	13	punct
11	Gen-Probe	NNP	12	nn
12	common	NN	13	nsubj
13	closed	VBD	0	root
14	at	IN	13	prep
15	$	$	14	pobj
16	3.25	CD	15	num
17	a	DT	18	det
18	share	NN	15	npadvmod
19	.	.	13	punct

1	Because	IN	4	mark
2	the	DT	3	det
3	U.S.	NNP	4	nsubj
4	leads	VBZ	24	advcl
5	in	IN	4	prep
6	most	JJS	7	amod
7	areas	NNS	5	pobj
8	of	IN	7	prep
9	biotechnology	NN	8	pobj
10	--	:	4	punct
11	largely	RB	13	advmod
12	because	IN	13	mwe
13	of	IN	4	prep
14	research	NN	15	nn
15	investment	NN	13	pobj
16	by	IN	15	prep
17	the	DT	19	det
18	U.S.	NNP	19	nn
19	government	NN	16	pobj
20	--	:	4	punct
21	the	DT	22	det
22	sale	NN	24	nsubj
23	is	VBZ	24	cop
24	sure	JJ	0	root
25	to	TO	26	aux
26	increase	VB	24	xcomp
27	concerns	NNS	26	dobj
28	that	IN	32	complm
29	Japanese	JJ	30	amod
30	companies	NNS	32	nsubj
31	will	MD	32	aux
32	buy	VB	27	ccomp
33	American	NNP	34	nn
34	know-how	NN	32	dobj
35	and	CC	32	cc
36	use	VB	32	conj
37	it	PRP	36	dobj
38	to	TO	39	aux
39	obtain	VB	36	xcomp
40	the	DT	42	det
41	upper	JJ	42	amod
42	hand	NN	39	dobj
43	in	IN	39	prep
44	biotechnology	NN	45	nn
45	trade	NN	43	pobj
46	and	CC	45	cc
47	competition	NN	45	conj
48	.	.	24	punct

1	``	``	14	punct
2	The	DT	4	det
3	biotechnology	NN	4	nn
4	firms	NNS	7	nsubj
5	may	MD	7	aux
6	be	VB	7	aux
7	setting	VBG	14	ccomp
8	up	RP	7	prt
9	their	PRP$	11	poss
10	own	JJ	11	amod
11	competitors	NNS	7	dobj
12	,	,	14	punct
13	''	''	14	punct
14	said	VBD	0	root
15	Richard	NNP	16	nn
16	Godown	NNP	14	nsubj
17	,	,	16	punct
18	president	NN	16	appos
19	of	IN	18	prep
20	the	DT	23	det
21	Industrial	NNP	23	nn
22	Biotechnology	NNP	23	nn
23	Association	NNP	19	pobj
24	.	.	14	punct

1	He	PRP	2	nsubj
2	added	VBD	0	root
3	that	IN	10	complm
4	until	IN	10	prep
5	now	RB	4	pcomp
6	the	DT	7	det
7	Japanese	NNS	10	nsubj
8	have	VBP	10	aux
9	only	RB	10	advmod
10	acquired	VBN	2	ccomp
11	equity	NN	12	nn
12	positions	NNS	10	dobj
13	in	IN	12	prep
14	U.S.	NNP	16	nn
15	biotechnology	NN	16	nn
16	companies	NNS	13	pobj
17	.	.	2	punct

1	``	``	11	punct
2	They	PRP	4	nsubj
3	are	VBP	4	aux
4	piggybacking	VBG	11	ccomp
5	onto	IN	4	prep
6	developed	VBN	7	amod
7	technology	NN	5	pobj
8	,	,	11	punct
9	''	''	11	punct
10	he	PRP	11	nsubj
11	said	VBD	0	root
12	.	.	11	punct

1	During	IN	10	prep
2	the	DT	5	det
3	past	JJ	5	amod
4	five	CD	5	num
5	years	NNS	1	pobj
6	,	,	10	punct
7	Japanese	JJ	8	amod
8	concerns	NNS	10	nsubj
9	have	VBP	10	aux
10	invested	VBN	0	root
11	in	IN	10	prep
12	several	JJ	11	pobj
13	of	IN	12	prep
14	the	DT	15	det
15	U.S.	NNP	20	poss
16	's	POS	15	possessive
17	431	CD	20	num
18	independent	JJ	20	amod
19	biotechnology	NN	20	nn
20	companies	NNS	13	pobj
21	.	.	10	punct

1	Chugai	NNP	4	nsubj
2	has	VBZ	4	aux
3	been	VBN	4	cop
4	one	CD	0	root
5	of	IN	4	prep
6	the	DT	10	det
7	most	RBS	8	advmod
8	active	JJ	10	amod
9	Japanese	JJ	10	amod
10	players	NNS	5	pobj
11	in	IN	10	prep
12	U.S.	NNP	14	nn
13	biotechnology	NN	14	nn
14	companies	NNS	11	pobj
15	;	:	4	punct
16	it	PRP	17	nsubj
17	has	VBZ	4	parataxis
18	an	DT	20	det
19	equity	NN	20	nn
20	investment	NN	17	dobj
21	in	IN	20	prep
22	Genetics	NNP	23	nn
23	Institute	NNP	24	nn
24	Inc.	NNP	21	pobj
25	,	,	24	punct
26	Cambridge	NNP	24	appos
27	,	,	26	punct
28	Mass.	NNP	26	appos
29	,	,	26	punct
30	and	CC	20	cc
31	a	DT	33	det
32	joint-venture	JJ	33	amod
33	agreement	NN	20	conj
34	with	IN	33	prep
35	Upjohn	NNP	36	nn
36	Co.	NNP	34	pobj
37	,	,	36	punct
38	Kalamazoo	NNP	36	appos
39	,	,	38	punct
40	Mich	NNP	38	appos
41	.	.	4	punct

1	The	DT	3	det
2	Japanese	JJ	3	amod
3	government	NN	10	nsubj
4	,	,	7	punct
5	Mr.	NNP	6	nn
6	Godown	NNP	7	nsubj
7	said	VBD	10	parataxis
8	,	,	7	punct
9	has	VBZ	10	aux
10	stated	VBN	0	root
11	that	IN	13	complm
12	it	PRP	13	nsubj
13	wants	VBZ	10	ccomp
14	10	CD	18	number
15	%	NN	18	dep
16	to	TO	18	dep
17	11	CD	18	number
18	%	NN	25	nsubj
19	of	IN	18	prep
20	its	PRP$	23	poss
21	gross	JJ	23	amod
22	national	JJ	23	amod
23	product	NN	19	pobj
24	to	TO	25	aux
25	come	VB	13	xcomp
26	from	IN	25	prep
27	biotechnology	NN	28	nn
28	products	NNS	26	pobj
29	.	.	10	punct

1	``	``	20	punct
2	It	PRP	4	nsubj
3	is	VBZ	4	aux
4	becoming	VBG	20	ccomp
5	more	JJR	4	attr
6	of	IN	5	prep
7	a	DT	9	det
8	horse	NN	9	nn
9	race	NN	6	pobj
10	every	DT	11	det
11	day	NN	4	tmod
12	between	IN	4	prep
13	the	DT	14	det
14	U.S.	NNP	12	pobj
15	and	CC	14	cc
16	Japan	NNP	14	conj
17	,	,	20	punct
18	''	''	20	punct
19	he	PRP	20	nsubj
20	said	VBD	0	root
21	,	,	20	punct
22	adding	VBG	20	xcomp
23	that	IN	25	complm
24	some	DT	25	nsubj
25	fear	VBP	22	ccomp
26	that	IN	41	complm
27	as	IN	41	prep
28	with	IN	27	pcomp
29	the	DT	36	det
30	semiconductor	NN	35	conj
31	,	,	35	punct
32	electronics	NNS	35	conj
33	,	,	35	punct
34	and	CC	35	cc
35	automobile	NN	36	nn
36	industries	NNS	28	pobj
37	,	,	41	punct
38	Japanese	JJ	39	amod
39	companies	NNS	41	nsubj
40	will	MD	41	aux
41	use	VB	25	ccomp
42	U.S.-developed	JJ	43	amod
43	technology	NN	41	dobj
44	to	TO	45	aux
45	gain	VB	41	xcomp
46	trade	NN	47	nn
47	advantages	NNS	45	dobj
48	.	.	20	punct

1	Mr.	NNP	2	nn
2	Bologna	NNP	3	nsubj
3	said	VBD	0	root
4	the	DT	5	det
5	sale	NN	7	nsubj
6	would	MD	7	aux
7	allow	VB	3	ccomp
8	Gen-Probe	NNP	10	nsubj
9	to	TO	10	aux
10	speed	VB	7	ccomp
11	up	RP	10	prt
12	the	DT	13	det
13	development	NN	10	dobj
14	of	IN	13	prep
15	new	JJ	16	amod
16	technology	NN	14	pobj
17	,	,	10	punct
18	and	CC	10	cc
19	to	TO	22	aux
20	more	RBR	21	advmod
21	quickly	RB	22	advmod
22	apply	VB	10	conj
23	existing	VBG	24	amod
24	technology	NN	22	dobj
25	to	TO	22	prep
26	an	DT	27	det
27	array	NN	25	pobj
28	of	IN	27	prep
29	diagnostic	JJ	30	amod
30	products	NNS	28	pobj
31	the	DT	32	det
32	company	NN	33	nsubj
33	wants	VBZ	30	rcmod
34	to	TO	35	aux
35	offer	VB	33	xcomp
36	.	.	3	punct

1	By	IN	33	prep
2	1988	CD	1	pobj
3	,	,	2	punct
4	when	WRB	18	advmod
5	only	RB	6	quantmod
6	10	CD	9	num
7	genetic	JJ	9	amod
8	probe-based	JJ	7	dep
9	tests	NNS	18	nsubjpass
10	of	IN	9	prep
11	diagnostic	JJ	13	amod
12	infectious	JJ	13	amod
13	diseases	NNS	10	pobj
14	of	IN	13	prep
15	humans	NNS	14	pobj
16	had	VBD	18	aux
17	been	VBN	18	auxpass
18	approved	VBN	2	dep
19	for	IN	18	prep
20	marketing	VBG	19	pobj
21	by	IN	18	prep
22	the	DT	26	det
23	Food	NNP	26	nn
24	and	CC	23	cc
25	Drug	NNP	23	conj
26	Administration	NNP	21	pobj
27	,	,	33	punct
28	eight	CD	33	nsubjpass
29	of	IN	28	prep
30	them	PRP	29	pobj
31	had	VBD	33	aux
32	been	VBN	33	auxpass
33	developed	VBN	0	root
34	and	CC	33	cc
35	sold	VBN	33	conj
36	by	IN	33	prep
37	Gen-Probe	NNP	36	pobj
38	.	.	33	punct

1	Osamu	NNP	2	nn
2	Nagayama	NNP	23	nsubj
3	,	,	2	punct
4	deputy	NN	5	nn
5	president	NN	2	appos
6	of	IN	5	prep
7	Chugai	NNP	6	pobj
8	,	,	7	punct
9	which	WDT	10	nsubj
10	spends	VBZ	7	rcmod
11	about	RB	12	quantmod
12	15	CD	13	num
13	%	NN	10	dobj
14	of	IN	13	prep
15	its	PRP$	16	poss
16	sales	NNS	14	pobj
17	on	IN	10	prep
18	research	NN	17	pobj
19	and	CC	18	cc
20	development	NN	18	conj
21	,	,	2	punct
22	was	VBD	23	cop
23	unable	JJ	0	root
24	to	TO	25	aux
25	pinpoint	VB	23	xcomp
26	how	WRB	27	advmod
27	much	JJ	28	amod
28	money	NN	31	dobj
29	Chugai	NNP	31	nsubj
30	would	MD	31	aux
31	pump	VB	25	ccomp
32	into	IN	31	prep
33	Gen-Probe	NNP	32	pobj
34	.	.	23	punct

1	``	``	15	punct
2	We	PRP	3	nsubj
3	think	VBP	15	ccomp
4	Gen-Probe	NNP	5	nsubj
5	has	VBZ	3	ccomp
6	technology	NN	5	dobj
7	important	JJ	6	amod
8	to	TO	7	prep
9	people	NNS	11	poss
10	's	POS	9	possessive
11	health	NN	8	pobj
12	,	,	15	punct
13	''	''	15	punct
14	he	PRP	15	nsubj
15	said	VBD	0	root
16	,	,	15	punct
17	adding	VBG	15	xcomp
18	:	:	17	punct
19	``	``	17	punct
20	We	PRP	21	nsubj
21	think	VBP	17	ccomp
22	it	PRP	24	nsubj
23	is	VBZ	24	cop
24	important	JJ	21	ccomp
25	for	IN	28	mark
26	us	PRP	28	nsubj
27	to	TO	28	aux
28	have	VB	24	advcl
29	such	JJ	30	amod
30	technology	NN	28	dobj
31	.	.	15	punct
32	''	''	15	punct

1	He	PRP	5	nsubj
2	and	CC	1	cc
3	Mr.	NNP	4	nn
4	Bologna	NNP	1	conj
5	emphasized	VBD	0	root
6	that	IN	10	complm
7	both	DT	8	det
8	companies	NNS	10	nsubj
9	would	MD	10	aux
10	gain	VB	5	ccomp
11	technological	JJ	12	amod
12	knowledge	NN	10	dobj
13	through	IN	10	prep
14	the	DT	15	det
15	sale	NN	13	pobj
16	of	IN	15	prep
17	Gen-Probe	NNP	16	pobj
18	,	,	17	punct
19	which	WDT	21	nsubj
20	will	MD	21	aux
21	expand	VB	17	rcmod
22	``	``	21	punct
23	significantly	RB	21	advmod
24	''	''	21	punct
25	as	IN	21	prep
26	a	DT	27	det
27	result	NN	25	pobj
28	of	IN	27	prep
29	the	DT	30	det
30	acquisition	NN	28	pobj
31	.	.	5	punct

1	In	IN	5	prep
2	1988	CD	1	pobj
3	,	,	5	punct
4	Chugai	NNP	5	nsubj
5	had	VBD	0	root
6	net	JJ	7	amod
7	income	NN	5	dobj
8	of	IN	7	prep
9	$	$	8	pobj
10	60	CD	9	number
11	million	CD	9	number
12	on	IN	5	prep
13	revenue	NN	12	pobj
14	of	IN	13	prep
15	$	$	14	pobj
16	991	CD	15	number
17	million	CD	15	number
18	.	.	5	punct

1	GenProbe	NN	2	nsubj
2	had	VBD	0	root
3	a	DT	5	det
4	net	JJ	5	amod
5	loss	NN	2	dobj
6	of	IN	5	prep
7	$	$	6	pobj
8	9.5	CD	7	number
9	million	CD	7	number
10	on	IN	2	prep
11	revenue	NN	10	pobj
12	of	IN	11	prep
13	$	$	12	pobj
14	5.8	CD	13	num
15	million	CD	13	num
16	.	.	2	punct

1	Recently	RB	4	advmod
2	,	,	4	punct
3	Gen-Probe	NNP	4	nsubj
4	received	VBD	0	root
5	a	DT	8	det
6	broad	JJ	8	amod
7	U.S.	NNP	8	nn
8	patent	NN	4	dobj
9	for	IN	8	prep
10	a	DT	11	det
11	technology	NN	9	pobj
12	that	WDT	13	nsubj
13	helps	VBZ	11	rcmod
14	detect	VB	13	xcomp
15	,	,	14	punct
16	identify	VB	14	conj
17	and	CC	14	cc
18	quantify	VB	14	conj
19	non-viral	JJ	20	amod
20	organisms	NNS	14	dobj
21	through	IN	14	prep
22	the	DT	21	pobj
23	targeting	VBG	22	amod
24	of	IN	22	prep
25	a	DT	26	det
26	form	NN	24	pobj
27	of	IN	26	prep
28	genetic	JJ	29	amod
29	material	NN	27	pobj
30	called	VBN	29	partmod
31	ribosomal	JJ	32	amod
32	RNA	NNP	30	dep
33	.	.	4	punct

1	Among	IN	7	prep
2	other	JJ	3	amod
3	things	NNS	1	pobj
4	,	,	7	punct
5	Mr.	NNP	6	nn
6	Bologna	NNP	7	nsubj
7	said	VBD	0	root
8	that	IN	12	complm
9	the	DT	10	det
10	sale	NN	12	nsubj
11	will	MD	12	aux
12	facilitate	VB	7	ccomp
13	Gen-Probe	NNP	15	poss
14	's	POS	13	possessive
15	marketing	NN	12	dobj
16	of	IN	15	prep
17	a	DT	19	det
18	diagnostic	JJ	19	amod
19	test	NN	16	pobj
20	for	IN	19	prep
21	acquired	VBN	24	amod
22	immune	JJ	23	amod
23	deficiency	NN	24	nn
24	syndrome	NN	20	pobj
25	,	,	24	punct
26	or	CC	24	cc
27	AIDS	NNP	24	conj
28	.	.	7	punct

1	Chugai	NNP	4	nsubj
2	also	RB	4	advmod
3	will	MD	4	aux
4	help	VB	17	ccomp
5	Gen-Probe	NNP	4	dobj
6	with	IN	4	prep
7	its	PRP$	11	poss
8	regulatory	JJ	11	amod
9	and	CC	8	cc
10	marketing	NN	8	conj
11	expertise	NN	6	pobj
12	in	IN	11	prep
13	Asia	NNP	12	pobj
14	,	,	17	punct
15	Mr.	NNP	16	nn
16	Bologna	NNP	17	nsubj
17	said	VBD	0	root
18	.	.	17	punct

1	The	DT	3	det
2	tender	NN	3	nn
3	offer	NN	9	nsubjpass
4	for	IN	3	prep
5	Gen-Probe	NNP	7	poss
6	's	POS	5	possessive
7	shares	NNS	4	pobj
8	is	VBZ	9	auxpass
9	expected	VBN	17	ccomp
10	to	TO	11	aux
11	begin	VB	9	xcomp
12	next	JJ	13	amod
13	Monday	NNP	11	tmod
14	,	,	17	punct
15	the	DT	16	det
16	company	NN	17	nsubj
17	said	VBD	0	root
18	.	.	17	punct


